Michael Youssef1, Ethan B Ludmir2,3, Jacob J Mandel2, Akash J Patel2, Ali Jalali2, Jeffrey Treiber2, Jimin Wu4, Mary Frances McAleer3, John F de Groot5. 1. Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Unit 431, 1515 Holcombe Blvd, Houston, TX, 77030-4009, USA. 2. Department of Neurology and Neurosurgery, Baylor College of Medicine, One Baylor Plaza, MS NB302, Houston, TX, 77030, USA. 3. Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Unit 1422, 1400 Pressler St, FCT6.5000, Houston, TX, 77030, USA. 4. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Unit 1409, P. O. Box 301402, Houston, TX, 77230-1402, USA. 5. Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Unit 431, 1515 Holcombe Blvd, Houston, TX, 77030-4009, USA. jdegroot@mdanderson.org.
Abstract
BACKGROUND/ PURPOSE: Optimal care for elderly patients with glioblastoma (GBM) remains in question due to their exclusion from and underrepresentation in many clinical trials (including EORTC 22,981) as well as their historically poor overall survival. METHODS: A retrospective chart review was conducted at a single high-volume cancer center for newly diagnosed elderly (65 years old or older) GBM patients diagnosed from 2011 through 2017. RESULTS: A total of 158 newly diagnosed GBM patients aged 65 years and older were identified. One hundred forty-four patients (91.1%) received radiotherapy (RT) and 130 patients (90.3%) received concurrent temozolomide with RT. Sixty-one patients (38.6%) completed concurrent chemoradiation and 6 cycles of adjuvant temozolomide. 23% of patients discontinued temozolomide during concurrent or adjuvant treatment due to side effects or complications of chemotherapy. With a median follow-up time of 35.0 months, median overall survival (OS) time for the full cohort was 18.6 months, with estimated OS rates of 74.8%, 35.9%, and 9.5% at 1, 2, and 5 years, respectively. On multivariable analysis, higher KPS (p = 0.002, HR 0.46; 95% CI 0.63-0.82), completing planned RT course (p = 0.01, HR 0.29; 95% CI 0.11-0.75), and completing 6 cycles of adjuvant temozolomide (p = 0.01, HR 2.62; 95% CI 1.67-4.12) were independently associated with improved OS. CONCLUSIONS: Our cohort of elderly GBM patients was predominantly treated with standard of care therapy based on EORTC 22,981. Despite their age, these patients generally tolerated treatment well and had favorable outcomes compared to those reported for patients treated on EORTC 22,981. Based on these findings, using advanced age as the basis for treatment de-escalation or as an exclusionary criterion in clinical trials should be discouraged.
BACKGROUND/ PURPOSE: Optimal care for elderly patients with glioblastoma (GBM) remains in question due to their exclusion from and underrepresentation in many clinical trials (including EORTC 22,981) as well as their historically poor overall survival. METHODS: A retrospective chart review was conducted at a single high-volume cancer center for newly diagnosed elderly (65 years old or older) GBMpatients diagnosed from 2011 through 2017. RESULTS: A total of 158 newly diagnosed GBMpatients aged 65 years and older were identified. One hundred forty-four patients (91.1%) received radiotherapy (RT) and 130 patients (90.3%) received concurrent temozolomide with RT. Sixty-one patients (38.6%) completed concurrent chemoradiation and 6 cycles of adjuvant temozolomide. 23% of patients discontinued temozolomide during concurrent or adjuvant treatment due to side effects or complications of chemotherapy. With a median follow-up time of 35.0 months, median overall survival (OS) time for the full cohort was 18.6 months, with estimated OS rates of 74.8%, 35.9%, and 9.5% at 1, 2, and 5 years, respectively. On multivariable analysis, higher KPS (p = 0.002, HR 0.46; 95% CI 0.63-0.82), completing planned RT course (p = 0.01, HR 0.29; 95% CI 0.11-0.75), and completing 6 cycles of adjuvant temozolomide (p = 0.01, HR 2.62; 95% CI 1.67-4.12) were independently associated with improved OS. CONCLUSIONS: Our cohort of elderly GBMpatients was predominantly treated with standard of care therapy based on EORTC 22,981. Despite their age, these patients generally tolerated treatment well and had favorable outcomes compared to those reported for patients treated on EORTC 22,981. Based on these findings, using advanced age as the basis for treatment de-escalation or as an exclusionary criterion in clinical trials should be discouraged.
Authors: L Paszat; N Laperriere; P Groome; K Schulze; W Mackillop; E Holowaty Journal: Int J Radiat Oncol Biol Phys Date: 2001-09-01 Impact factor: 7.038
Authors: Victor M Lu; Panogiotis Kerezoudis; Desmond A Brown; Terry C Burns; Alfredo Quinones-Hinojosa; Kaisorn L Chaichana Journal: J Neurooncol Date: 2019-03-27 Impact factor: 4.130
Authors: Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: William C Jackson; Christina I Tsien; Larry Junck; Denise Leung; Shawn Hervey-Jumper; Daniel Orringer; Jason Heth; Daniel R Wahl; Daniel E Spratt; Yue Cao; Theodore S Lawrence; Michelle M Kim Journal: J Neurooncol Date: 2018-02-01 Impact factor: 4.130
Authors: Alireza Mansouri; Laureen D Hachem; Sheila Mansouri; Farshad Nassiri; Normand J Laperriere; Daniel Xia; Neal I Lindeman; Patrick Y Wen; Arnab Chakravarti; Minesh P Mehta; Monika E Hegi; Roger Stupp; Kenneth D Aldape; Gelareh Zadeh Journal: Neuro Oncol Date: 2019-02-14 Impact factor: 12.300
Authors: Antje Wick; Tobias Kessler; Andrew E H Elia; Frank Winkler; Tracy T Batchelor; Michael Platten; Wolfgang Wick Journal: Neuro Oncol Date: 2018-01-22 Impact factor: 12.300
Authors: Monika E Hegi; Annie-Claire Diserens; Sophie Godard; Pierre-Yves Dietrich; Luca Regli; Sandrine Ostermann; Philippe Otten; Guy Van Melle; Nicolas de Tribolet; Roger Stupp Journal: Clin Cancer Res Date: 2004-03-15 Impact factor: 12.531
Authors: Ramin A Morshed; Jacob S Young; Megan Casey; Elaina J Wang; Manish K Aghi; Mitchel S Berger; Shawn L Hervey-Jumper Journal: World Neurosurg Date: 2022-02-15 Impact factor: 2.210